Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition and Safety in Patients... | NCT02175693 | Trialant
CompletedObservationalUpdated Jan 9, 2020
Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition and Safety in Patients With Cervical Dystonia
ClinicalTrials.gov ID
NCT02175693
Lead Sponsor
Eisai Co., Ltd.INDUSTRY
Overall Status
Completed
Study Type
Observational
Enrollment
1,647Actual
Last Update Posted
Jan 9, 2020Actual
Start Date
Apr 2, 2013Actual
Primary Completion Date
Jun 30, 2019Actual
Completion Date
Jun 30, 2019Actual
Brief Summary
Investigation of the clinical condition and safety in patients with cervical dystonia
Cervical Dystonia
No interventions
There are no interventions for this study.
Ages Eligible for Study
Child (0-17)Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Patients with cervical dystonia
Exclusion criteria:
The patients who participated in this surveillance in the past